BioCryst Pharmaceuticals BCRX Interest paid, royalty financing obligations
Interest paid, royalty financing obligations at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:InterestPaidRoyaltyFinancingLiabilities.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's interest paid, royalty financing obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's interest paid, royalty financing obligations?
- BioCryst Pharmaceuticals (BCRX) reported interest paid, royalty financing obligations of $8.47M in Q1 2026.
- How has BioCryst Pharmaceuticals's interest paid, royalty financing obligations changed year-over-year?
- BioCryst Pharmaceuticals's interest paid, royalty financing obligations decreased by 41.8% year-over-year, from $14.55M to $8.47M.
- What is the long-term trend for BioCryst Pharmaceuticals's interest paid, royalty financing obligations?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's interest paid, royalty financing obligations has grown at a 52.7% compound annual growth rate (CAGR), from $29.34M to $68.43M.
- What does interest paid, royalty financing obligations mean?
- This reflects the cash interest payments made on debt instruments specifically structured as royalty financing. Unlike traditional debt, these obligations are often tied to the performance of specific drug assets or revenue streams. It is a critical indicator of the cost of capital for companies that monetize future royalties to fund current operations.